Background: Certain antiretrovirals are known to affect lipid and glucose homeostasis. The aim of this study was to assess the effect on insulin sensitivity (determined by peripheral glucose uptake using a hyperinsulinaemic euglycaemic clamp) of tenofovir disoproxil fumarate (TDF) administration compared with placebo for 2 weeks in HIV-1-seronegative healthy male volunteers. Changes in lipids, adiponectin, leptin, plasminogen activator inhibitor 1 (PAI-1) and the adhesion molecules E-selectin and P-selectin were also assessed. Methods: This was a single-centre, randomized, doubleblinded, placebo-controlled study that used a twosequence, two-period cross-over design. A total of 19 HIV-negative males were recruited to the study and randomized 1:1 to receive either 2 weeks of TDF (300 mg once daily) followed by 2 weeks of placebo or placebo initially followed by tenofovir. Clamps were performed at baseline, after 2 weeks and after 4 weeks. Results: All three clamps were completed by 16 participants. During the euglycaemic clamp, there were no significant changes in insulin sensitivity after 2 weeks of TDF administration compared with placebo or baseline. There was a significant reduction in the mean total cholesterol (9.4%) and low-density lipoprotein (LDL; 8.1%) cholesterol following 2 weeks of TDF compared with placebo. Levels of adiponectin, leptin, PAI-1, P-selectin and E-selectin were not significantly altered. Conclusions: TDF use for 2 weeks does not affect insulin sensitivity, as assessed by the hyperinsulinaemic euglycaemic clamp in HIV-negative male volunteers. TDF use resulted in modest, but statistically significant, reductions in total and LDL cholesterol.
Effective antiretroviral therapy has improved mortality [1] and reduced morbidity associated with HIV infection. As HIV-infected patients are living longer, chronic prevalent diseases of aging, particularly ischaemic heart disease and type 2 diabetes mellitus, are becoming important causes of morbidity and mortality. Specific antiretrovirals have been associated with risk of myocardial infarction [2] , diabetes mellitus [3] and the development of metabolic and morphological disturbances including dyslipidaemia, insulin resistance and body-fat changes [4] . These changes differ between drug classes and between drugs in the same class. As the choice of antiretroviral regimen can influence cardiovascular and diabetes mellitus disease risk, it is necessary to understand the metabolic effect of individual drugs to help inform this choice.
The hyperinsulinaemic euglycaemic clamp [5] is the gold standard for investigating insulin sensitivity in a research setting and has been used to investigate the effect of different antiretrovirals on glucose homeostasis. A number of protease inhibitors (PIs) [6] [7] [8] [9] [10] [11] and nucleoside reverse transcriptase inhibitors (NRTIs) [12, 13] have been associated with the development of insulin resistance. Mitochondrial toxicity is implicated in the development of insulin resistance associated with thymidine NRTIs [12, 13] , whereas with PIs insulin resistance appears to be mediated through the inhibition of the glucose transporter GLUT4 [14] .
This study investigated in healthy HIV-negative volunteers the effect of tenofovir disoproxil fumarate (TDF) on whole-body insulin sensitivity, as assessed by the hyperinsulinaemic euglycaemic clamp. In addition,
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Methods

Study design
This was a single-centre, double-blinded, placebocontrolled study using a two-sequence, two-period cross-over design. Eligible participants were randomized 1:1 to receive either 2 weeks of TDF (300 mg orally, once daily) followed by matching placebo for 2 weeks or commenced with placebo followed by active TDF. A hyperinsulinaemic euglycaemic clamp was performed at baseline and then at weeks 2 and 4 (2 weeks after treatment switch). Fasting samples for lipids, adiponectin, leptin, PAI-1, E-selectin and P-selectin were also taken at these visits.
Eligibility criteria
The study was approved by the Hammersmith research ethic committee and conducted according to the principles of good clinical practice. Participants gave informed consent and were screened up to 28 days prior to their baseline visit. Male participants were included if they were aged between 18 and 55 years, were clinically well, and not receiving any metabolically active or lipidlowering medication, hormonal agents, glucocorticoids, β-blockers, thiazide diuretics, thyroxine, psychotropic agents, anabolic steroids, megestrol acetate, nephrotoxic agents, chemotherapeutic agents or immunomodulating agents. Fasting glucose and lipid parameters were required to be less than the upper limit of normal: for glucose <6.0 mmol/l (109 mg/dl), triglycerides <2.0 mmol/l (182 mg/dl) and cholesterol <5.0 mmol/l (192 mg/dl). Creatinine clearance was assessed using the CockcroftGault formula and participants were only included if the calculated creatinine clearance was >100 ml/min. Other relevant exclusion criteria included a waist:hip ratio >0.97, a body mass index (BMI) >28 kg/m 2 , acute or chronic hepatitis B or C infection, diabetes mellitus or any disease process likely to cause a marked disturbance in glucose and lipid homeostasis.
Hyperinsulinaemic euglycaemic clamp
Participants were admitted to the research unit after an overnight fast of at least 8 h. An intravenous cannula was inserted into the right antecubital fossa for infusion of insulin and a 20% glucose solution. A retrograde cannula was inserted in the back of the distal third of the left forearm, which was heated to 55°C in a thermoregulated box. This was used for blood sampling for the duration of the 180 min clamp procedure. At t=0 a continuous infusion of insulin (Actrapid ® , 100 IU/ ml, Novo Nordisk A/S, Bagsvaerd, Denmark) was commenced at 80 mU/m 2 /min. At t=5 min, the rate was reduced to 60 mU/m 2 /min until t=10 min when it was reduced to 40 mU/m 2 /min and continued at this rate for the remainder of the clamp. At t=4 min the 20% glucose solution was commenced and from t=10 min the plasma glucose was analysed (using the i-STAT ® Analyser; iSTAT Corporation, East Windsor, NJ, USA) every 5 min. A negative feedback formula [5] was used to adjust the rate of glucose infusion in order to maintain euglycaemia at 4.5 mmol/l. Serial electrocardiograms and whole-blood potassium were monitored during the clamp procedure. Blood samples where taken at t=120 min, 150 min and 180 min to determine average insulin concentration during the last hour of the clamp [5] . Insulin sensitivity was assessed by calculating the ratio M/I (glucose disposal rate [M] , during the last hour of the clamp, divided by average insulin concentration [I] over this time). In addition, the homeostatic model assessment index-insulin resistance (HOMA-IR) was calculated using the formula: (fasting insulin × fasting glucose)/22.5 was calculated at each visit.
Statistical analyses
The primary objective of the study was to assess the effect of the administration of TDF compared with placebo for 2 weeks in HIV-1-negative healthy male volunteers using the hyperinsulinaemic euglycaemic clamp. Results were analysed to assess for any period effect. Subsequently, the mean insulin-stimulated glucose disposal (M/I: mg/kg/min per mU/l insulin ×100) in the TDF group was compared with the placebo group using the Wilcoxon signed-rank test.
Results
A total of 19 participants were randomized. Three participants withdrew prior to the baseline visit; the remaining 16 completed all study assessments. Nine participants received placebo followed by TDF and seven received TDF followed by placebo. There were no significant differences in baseline characteristics between the two groups. The participants ranged in age from 19 to 37 years with a mean of 27.4 years. Mean (±sd) BMI was 23.02 kg/m 2 (±1.665); the mean (±sd) for the waist:hip ratio was 0.88 (±0.037).
Overall, the mean (±sd) insulin concentrations achieved during the last hour of the clamps were 58.66 (±15.51) mU/l, 58.56 (±15.00) mU/l and 58.23 (±15.99) mU/l for the 120, 150 and 180 min time points, respectively. Boxplots of the ratio of insulin concentrations over these time points to the insulin concentration at 120 min are presented in Figure 1 , to better illustrate the variability observed. There was no significant effect on whole-body insulin sensitivity, as assessed by the glucose disposal rate M or M/I during the final hour of the clamp during the TDF and placebo treatment periods. No significant period effect was observed between groups. In the placebo group, two patients experienced marked increases in the M/I ratio compared with baseline (Figure 2) . No procedural errors were noted during these time points and these results have been included in the analysis; however, the outcomes are the same whether these individuals are included or excluded. HOMA-IR was also not significantly altered. There was no significant difference between the two groups (see Table 1 ).
Lipid parameters are presented in Figure 3 . Mean total cholesterol was reduced by 9.4% compared with baseline (P=0.004) after dosing with 2 weeks of TDF. A statistically significant reduction was also seen compared with placebo (P=0.017). This reduction was predominantly due to an 8.1% reduction in low-density lipoprotein (LDL) cholesterol (P=0.025 for the change from baseline in the TDF treatment period). There were no significant changes in lipids after 2 weeks of placebo. Neither TDF nor placebo had any significant effect on adiponectin, leptin, PAI-1, P-selectin or E-selectin (Figure 4) .
No serious adverse events were experienced by the participants during the course of the study. There was no development of grade 3 or 4 laboratory results in either group. Adverse events were mild with upper respiratory tract infection the commonest adverse event (three in each group). Other adverse events reported (by individual participants) were headache, nausea and thrombophlebitis in the placebo group and non-cardiac chest pain, fatigue and back injury in the TDF group.
Discussion
Studies using the hyperinsulinaemic clamp have demonstrated variable effects of antiretrovirals on glucose homeostasis. In healthy volunteers, single doses of lopinavir/ritonavir [6, 7, 11] have resulted in a reduction in insulin-mediated glucose disposal. A hierarchy of the acute effect PIs have on insulin sensitivity has been proposed: indinavir causes the greatest reduction followed by ritonavir and lopinavir/ritonavir, whereas amprenavir has no effect [7] . Neither atazanavir given for 5 days [10] nor atazanavir coadministered with ritonavir for 10 days [8] significantly affected insulin-mediated glucose disposal. Although an approximate 25% reduction in the glucose disposal rate was seen after 5 days [10] and 10 days [8] of lopinavir/ritonavir, no change was seen after 4 weeks of dosing [15] . Four weeks of indinavir treatment led to a 20% reduction in insulin-mediated glucose disposal rate, independent from changes in lipids and visceral fat [9] , compared with a 34% reduction acutely [11] . Both 4 weeks of indinavir and lopinavir/ ritonavir were associated with an increase in adiponectin [16] , which might be responsible for ameliorating the initial effect of these PIs on insulin sensitivity.
NRTIs have also been implicated in the development of insulin resistance. Stavudine given for 1 month in healthy volunteers resulted in a significant reduction in glucose infusion rates during the clamp. This was associated with a 52% reduction in mitochondrial DNA [13] . In the MEDICLAS substudy, HIV-positive patients in the NRTI arm (lopinavir/ritonavir plus lamivudine plus zidovudine) showed a 25% reduction in insulin-stimulated glucose disposal at 3 months, which was in contrast to the NRTI-sparing arm (lopinavir/ ritonavir plus nevirapine) where glucose metabolism was not affected [12] . These findings are consistent with those from the D:A:D study group, which found that cumulative exposure to stavudine and zidovudine were significantly associated with diabetes mellitus in a large HIV-positive cohort [3] .
In our study, 2 weeks of TDF administration did not significantly affect insulin sensitivity during the hyperinsulinaemic euglycaemic clamp, as measured by the glucose disposal rate (M) and the ratio M/I. In addition, there was no significant affect on the HOMA-IR. These findings are consistent with a lack of any significant mitochondrial toxicity associated with TDF [17] . Furthermore, the absence of an increase in adiponectin indicates a lack of compensatory changes in glucose handling. Changes seen in healthy volunteer studies are not necessarily observed in HIV-infected individuals [12, 18, 19] , but the results of this study are consistent with the lack of a significant effect on insulin sensitivity seen when TDF has been used as part of the antiretroviral combination in patients initiating treatment [18, 19] .
Dyslipidaemia and insulin resistance are important contributors to cardiovascular risk and can be modified by antiretroviral treatment [4] . Studies have demonstrated a more favourable lipid profile of TDF relative to stavudine [20] and zidovudine [21] , and when switching from stavudine [22] or zidovudine to TDF [23, 24] . In our study, there was a statistically significant improvement in total cholesterol after 2 weeks of dosing with TDF compared with placebo and baseline. Importantly, this reduction was driven mainly by a reduction in LDL cholesterol. The mechanism of this effect is not known, but has also been observed in studies where TDF has been used as an intensification agent [25] .
In our study we evaluated selected biomarkers in an attempt to further assess the metabolic effect of TDF. The adipokine adiponectin has an important role in In all panels, the median value is plotted together with the interquartile range. TDF, tenofovir disoproxil fumarate. the regulation of energy metabolism. Decreased levels have been found to be associated with insulin resistance [26] and it appears to have a protective role against the development of atherosclerosis [27] . Leptin is also involved in energy metabolism and serves as a marker of energy stores and regulates neuroendocrine, immunological and metabolic function, in energy-deficient states [28] [29] [30] . The dysregulation of adiponectin and leptin have been implicated in the pathogenesis of the metabolic syndrome associated with antiretroviral therapy (ART) [31] . PAI-1 has a role in thrombotic vascular disease [32] and increased levels have been seen in patients receiving PI-containing ART [33] . Increased endothelial adhesion molecules [34, 35] (including E-selectin) have been associated with HIV and can be used as a marker of endothelial function. In this study, TDF did not appear to affect adipokine output or markers of endothelial function. A limitation of this study is the short period of followup; further investigation to assess the effect of TDF on these biomarkers beyond 2 weeks would be useful.
In conclusion, dosing with TDF for 2 weeks did not have a significant effect on whole-body insulin sensitivity, as assessed using the hyperinsulinaemic euglycaemic clamp, compared with placebo and with baseline in HIV-negative volunteers. In addition, there was no significant effect on the adipokines (adiponectin, leptin and PAI-1) or on the adhesion molecules E-selectin and P-selectin. There was a statistically significant decrease in total cholesterol (compared with placebo and baseline) and LDL cholesterol (compared with baseline) after 2 weeks of TDF.
